StockData

Arvinas vs Xencor

ARVN and XNCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ARVN and XNCR compare

Xencor is the larger company, worth 5.8 times as much as Arvinas ($2.6B against $446M).

Arvinas grew revenue faster over the last twelve months (−15.0% versus −28.6% for Xencor).

Arvinas keeps more of each dollar of sales as profit, with a net margin of 2.9% compared with −156% at Xencor.

Arvinas scores higher on the StockData Score (8 against 5 for Xencor), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricARVNXNCR
Size and price
Market cap$446M$2.6B
Share price$6.82$34.50
Change, 1 year−35.5%131%
Change, 5 years−91.3%−2.7%
Beta (5Y)2.00−0.05
Employees246260
StockData Score
Total score8 (better)5
Valuation score1 (better)0
Growth score11
Performance score3 (better)1
Health score33
Dividend score00
Valuation
P/E42.6×–
P/S1.4× (better)24.4×
P/B0.8× (better)5.1×
FCF yield−46.8%−8.1% (better)
Fair value–$11.73
Margin of safety–−194%
Growth
Revenue growth (TTM)−15.0% (better)−28.6%
Revenue growth, 5Y average58.9% (better)0.47%
Profitability
Operating margin−5.7% (better)−206%
Net margin2.9% (better)−156%
FCF margin−65.9% (better)−198%
Return on equity1.6% (better)−29.1%
Return on invested capital–−26.6%
Financial health
Debt / equity0.00 (better)0.21
Interest coverage–−8.0×
Current ratio7.91 (better)6.39
Altman Z-score0.655.01 (better)
Piotroski F-score4 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions86.0%113%
Held by insiders7.8%1.6%
Insider net buying, 12 months−$1.2M (better)−$7.5M
Short interest, % of float9.5%17.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.